

Oxurion ontvangt transparantiekennisgeving van Atlas Special Opportunities LLC

Leuven, BELGIË, Boston, MA, VS – 12 juni 2023 – 20.00 uur CET [Oxurion NV](#) (Euronext Brussel: OXUR), een biofarmaceutisch bedrijf dat de volgende generatie zorgstandaard oogheekundige therapieën ontwikkelt, met klinische activa in vasculaire retinale aandoeningen, heeft vandaag aangekondigd dat het in overeenstemming met de Belgische transparantiewetgeving¹, de volgende transparantiekennisgevingen heeft ontvangen:

Oxurion ontving op 7 juni 2023 een transparantiekennisgeving van Atlas Special Opportunities LLC waaruit blijkt dat het op 30 mei 2023 21.494.943 aandelen van de toen uitstaande 896.925.569 aandelen bezat en dus onder de drempel (3%) kwam door de verkoop van stemrechtverlenende effecten. Zie bijlage 1.

Oxurion ontving op 7 juni 2023 een transparantiekennisgeving van Atlas Special Opportunities LLC waaruit blijkt dat het op 1 juni 2023 71.192.352 aandelen van de toen uitstaande 1.022.343.629 aandelen bezat en dus onder de drempel (10%) kwam door de verwerving en verkoop van stemrechtverlenende effecten. Zie bijlage 2.

Oxurion ontving op 9 juni 2023 een transparantiekennisgeving van Atlas Special Opportunities LLC waaruit blijkt dat het op 2 juni 2023 19.092.777 aandelen van de toen uitstaande 1.022.343.629 aandelen bezat en dus onder de drempel (3%) kwam door de verkoop van stemrechtverlenende effecten. Zie bijlage 3.

Over Oxurion

Oxurion (Euronext Brussel: OXUR) is een biofarmaceutisch bedrijf dat de volgende generatie zorgstandaard oogheekundige therapieën ontwikkelt, die zijn ontworpen om het gezichtsvermogen te verbeteren en beter te behouden bij patiënten met retinale aandoeningen, waaronder diabetisch macula-oedeem (DME), de belangrijkste oorzaak van verlies van het gezichtsvermogen bij mensen in de werkende leeftijd, evenals andere aandoeningen. Oxurion beoogt een belangrijke rol te spelen in de behandeling van retinale aandoeningen, waaronder de succesvolle ontwikkeling van THR-149, de nieuwe therapeutische voor de behandeling van DME. THR-149 is een krachtige plasma kallikreïneremmer die wordt ontwikkeld als een potentiële nieuwe zorgstandaard voor maximaal 50% van de DME-patiënten die een suboptimale respons op anti-VEGF-therapie vertonen. Oxurion heeft haar hoofdkantoor in Leuven, België, met bedrijfsactiviteiten in Boston, MA. Meer informatie is beschikbaar op www.oxurion.com.

Belangrijke informatie over toekomstgerichte verklaringen

Bepaalde verklaringen in dit persbericht kunnen als "toekomstgericht" worden beschouwd. Dergelijke toekomstgerichte verklaringen zijn gebaseerd op de huidige verwachtingen en brengen dienovereenkomstig verschillende risico's en onzekerheden met zich mee en worden ze beïnvloed. Het bedrijf kan daarom geen enkele garantie geven dat dergelijke toekomstgerichte verklaringen zullen materialiseren en aanvaardt geen enkele verplichting om een toekomstgerichte verklaring bij te werken of te herzien, hetzij als gevolg van nieuwe informatie, toekomstige gebeurtenissen of enige andere reden. Aanvullende informatie over risico's en onzekerheden die van invloed zijn op het bedrijf

en andere factoren die ertoe kunnen leiden dat de werkelijke resultaten wezenlijk verschillen van een toekomstgerichte verklaring, is opgenomen in het jaarverslag van het bedrijf. Dit persbericht vormt geen aanbod of uitnodiging voor de verkoop of aankoop van effecten of activa van Oxurion in enig rechtsgebied. Er mogen geen effecten van Oxurion worden aangeboden of verkocht in de Verenigde Staten zonder registratie onder de U.S. Securities Act van 1933, zoals gewijzigd, of in overeenstemming met een vrijstelling daarvan, en in overeenstemming met toepasselijke Amerikaanse effectenwetten.

Voor meer informatie kunt u contact opnemen met:

<p><u>Oxurion NV</u> Tom Graney Chief Executive Officer Tel: +32 16 75 13 10 tom.graney@oxurion.com</p> <p>Michael Dillen Chief Business Officer Tel: +32 16 75 13 10 michael.dillen@oxurion.com</p>	<p><u>US</u> <u>Conway Communications</u> Mary T. Conway mtconway@conwaycommsir.com</p> <p><u>ICR Westwicke</u> Christopher Brinzey Tel: +1 617 835 9304 Chris.Brinzey@westwicke.com</p>
--	---

1. Artikel 14, eerste alinea, van de Wet van 2 mei 2007 betreffende de openbaarmaking van belangrijke deelnemingen.

BIJLAGE 1

1) Status of the notification

Final

2) Issuer

Name OXURION
Identification number 0881-620-924

3) Reason for the notification

Acquisition or disposal of voting securities or voting rights
Downward crossing of the lowest threshold

-
+

4) Notification by

A person that notifies alone

+

5) Persons subject to the notification requirement

Name	Address (for legal entities)
Atlas Special Opportunities LLC	2500 Westchester Avenue, Suite 401, Purchase, NY 10577

+

6) Persons that dispose of voting rights (only to be filled in if art. 7 of the Law applies)

Name	Address (for legal entities)

+

 Please continue entering the information in **part II** concerning the persons referred to in Sections 5 and 6


Part II

7) Date on which the threshold is crossed

30/05/2023 (DD/MM/YYYY)

8) Threshold that is crossed (in %)

3

 If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10

9) Denominator

896,925,569

 Please enter the denominator before filling in the data

10) Notified details


A) Voting rights	Previous notification	After the transaction			
	# of voting rights	# of voting rights		% of voting rights	
Holders of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
Atlas Special Opportunities LLC	32,301,799	21,494,943		2.40%	
TOTAL		21,494,943	0	2.40%	0.00%

+

 Start with "groups" of holders. Add subtotals with Σ , and then finish with the persons who are "alone".
For groups, start with the ultimate controlling natural person or legal entity.
The totals, subtotals and % will be updated once you have clicked on **<CALCULATE>**.

B) Equivalent financial instruments	After the transaction					
	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
TOTAL				0	0.00%	

+

 The totals will be updated once you have clicked on **<CALCULATE>**

TOTAL (A & B)		# of voting rights	% of voting rights
	CALCULATE	21,494,943	2.40%

11) Full chain of controlled undertakings through which the holding is effectively held, if applicable

Atlas Special Opportunities LLC is not a controlled entity.

12) In case of proxy voting for only one GM

Holder will cease to hold / will hold again 0 voting rights as of (DD/MM/YYYY)

13) Additional information

Atlas Special Opportunities LLC held 45,289,855 shares in Oxurion NV on 30/05/2023 (= 5.05%).
On 30/05/2023 Atlas Special Opportunities LLC sold 23,794,912 shares in Oxurion NV, as a result of which its shareholding decreased to 21,494,943 shares (= 2.40%).

Done at New York

On 07/06/2023 (DD/MM/YYYY)

Name & capacity Patrick Vance, proxyholder

Signature Patrick Vance

BIJLAGE 2

 FSMA FINANCIAL SERVICES AND MARKETS AUTHORITY	Transparency notification Form TR-1 BE PART I
--	--

1) Status of the notification

Final

2) Issuer

Name: OXURION
Identification number: 0881-620-924

3) Reason for the notification

Acquisition or disposal of voting securities or voting rights



4) Notification by

A person that notifies alone



5) Persons subject to the notification requirement

Name	Address (for legal entities)
Atlas Special Opportunities LLC	2500 Westchester Avenue, Suite 401, Purchase, NY 10577



6) Persons that dispose of voting rights (only to be filled in if art. 7 of the Law applies)

Name	Address (for legal entities)



 Please continue entering the information in **part II** concerning the persons referred to in Sections 5 and 6


Part II

7) Date on which the threshold is crossed

01/06/2023 (DD/MM/YYYY)


8) Threshold that is crossed (in %)

10

 If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10


9) Denominator

1,022,343,629


 Please enter the denominator before filling in the data

10) Notified details

A) Voting rights	Previous notification	After the transaction			
	# of voting rights	# of voting rights		% of voting rights	
Holders of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
Atlas Special Opportunities LLC	21,494,943	71,192,352		6.96%	
TOTAL		71,192,352	0	6.96%	0.00%

 Start with "groups" of holders. Add subtotals with Σ , and then finish with the persons who are "alone".
For groups, start with the ultimate controlling natural person or legal entity.
The totals, subtotals and % will be updated once you have clicked on **<CALCULATE>**.

B) Equivalent financial instruments	After the transaction					
	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
TOTAL				0	0.00%	

 The totals will be updated once you have clicked on **<CALCULATE>**

TOTAL (A & B)	# of voting rights	% of voting rights
CALCULATE	71,192,352	6.96%

11) Full chain of controlled undertakings through which the holding is effectively held, if applicable

Atlas Special Opportunities LLC is not a controlled entity.

12) In case of proxy voting for only one GM

Holder will cease to hold / will hold again 0 voting rights as of (DD/MM/YYYY)

13) Additional information

Atlas Special Opportunities LLC held 21,494,943 shares in Oxunion NV on 30/05/2023 (= 2.40%).
On 31/05/2023 Atlas Special Opportunities LLC received 125,418,060 shares and subsequently sold 34,702,011 shares, as a result of which its shareholding increased to 112,210,992 shares (= 10.97%). On 01/06/2023 Atlas Special Opportunities LLC sold 41,018,640 shares, as a result of which its shareholding decreased to 71,192,352 shares (= 6.96%).

Done at New York

On 07/06/2023 (DD/MM/YYYY)

Name & capacity Patrick Vance, proxyholder

Signature Patrick Vance

BIJLAGE 3

1) Status of the notification

Final

2) Issuer

Name OXURION
Identification number 0881-620-924

3) Reason for the notification

Acquisition or disposal of voting securities or voting rights
Downward crossing of the lowest threshold

-
+

4) Notification by

A person that notifies alone

+

5) Persons subject to the notification requirement

Name	Address (for legal entities)
Atlas Special Opportunities LLC	2500 Westchester Avenue, Suite 401, Purchase, NY 10577

+

6) Persons that dispose of voting rights (only to be filled in if art. 7 of the Law applies)

Name	Address (for legal entities)

+

 Please continue entering the information in **part II** concerning the persons referred to in Sections 5 and 6


Part II

7) Date on which the threshold is crossed

02/06/2023 (DD/MM/YYYY)

8) Threshold that is crossed (in %)

3

 If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10


9) Denominator

1,022,343,629


 Please enter the denominator before filling in the data

10) Notified details

A) Voting rights	Previous notification	After the transaction			
	# of voting rights	# of voting rights		% of voting rights	
Holder of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
Atlas Special Opportunities LLC	71,192,352	19,092,777		1.87%	
TOTAL		19,092,777		1.87%	

 Start with "groups" of holders. Add subtotals with Σ and then finish with the persons who are "alone".
For groups, start with the ultimate controlling natural person or legal entity.
The totals, subtotals and % will be updated once you have clicked on <CALCULATE>.

B) Equivalent financial instruments	After the transaction					
	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
Holder of equivalent financial instruments						
TOTAL						

 The totals will be updated once you have clicked on <CALCULATE>

TOTAL (A & B)		# of voting rights	% of voting rights
	CALCULATE	19,092,777	1.87%

11) Full chain of controlled undertakings through which the holding is effectively held, if applicable

Atlas Special Opportunities LLC is not a controlled entity.

12) In case of proxy voting for only one GM

Holder will cease to hold / will hold again (DD/MM/YYYY) voting rights as of

13) Additional information

Atlas Special Opportunities LLC held 71,192,352 shares in Oxurion NV on 01/06/2023 (= 6.96%).
On 02/06/2023 Atlas Special Opportunities LLC sold 52,099,575 shares, as a result of which its shareholding decreased to 19,092,777 shares (= 1.87%). On 05/06/2023 Atlas Special Opportunities LLC sold 19,092,777 shares, as a result of which its shareholding decreased to 0 shares (= 0.00%).

Done at New York

On 08/06/2023 (DD/MM/YYYY)

Name & capacity Patrick Vance, proxyholder

Signature Patrick Vance